Clinicians play a key role in ensuring early and accurate Alzheimer's disease diagnosis, as well as access to treatments and quality care. Understanding amyloid-targeting antibodies for the treatment of Alzheimer's can help patients and their caregivers to cope with symptoms and improve quality of life.
The amyloid-targeting therapies on this page target and remove beta-amyloid from the brain and reduce cognitive and functional decline in people living with early Alzheimer's, including people living with mild cognitive impairment (MCI) or mild dementia due to Alzheimer's disease.
Aducanumab (Aduhelm®)
Aducanumab (Aduhelm) is an anti-amyloid antibody intravenous (IV) infusion therapy that is delivered every month. It received accelerated approval from the Food and Drug Administration (FDA) to treat early Alzheimer's disease, including people living with mild cognitive impairment (MCI) or mild dementia due to Alzheimer's disease who have confirmation of elevated beta-amyloid in the brain.
Aducanumab is being discontinued. People who are now receiving the drug as part of a clinical trial will continue to have access to it until May 1, 2024; people who are now receiving it by prescription will have it available to them until Nov. 1, 2024.
Learn more about aducanumab's appropriate use recommendations.
Lecanemab (Leqembi®)
Lecanemab (Leqembi) is an anti-amyloid antibody intravenous (IV) infusion therapy that is delivered every two weeks. It received traditional approval from the FDA to treat early Alzheimer's disease, including people living with mild cognitive impairment (MCI) or mild dementia due to Alzheimer's disease who have confirmation of elevated beta-amyloid in the brain.
Learn more about lecanemab and its appropriate use recommendations.
Donanemab
Phase 3 clinical trial results reported in July 2023 showed that the drug donanemab significantly slowed cognitive and functional decline in people living with early symptomatic Alzheimer's disease (either mild cognitive impairment or mild dementia).
Donanemab is unapproved by the FDA and is currently under review.
For more information
For information about approved and available Alzheimer's disease treatments, contact the Alzheimer's Association Health Systems and Medical Professionals team using this form.
2024 ARIA Workgroup
In March 2024, the Alzheimer's Association established a workgroup consisting of experts in the fields of basic science, neuropathology, neuroradiology and bioethics to discuss growth, as well as current gaps, in knowledge regarding amyloid-related imaging abnormalities (ARIA). While the workgroup's discussions are currently ongoing, the preliminary objective is to equip the scientific and clinical community with a comprehensive understanding of the latest knowledge on ARIA, as well as recommend directions for future research.